Cell interventions in neurological disease: use an evidence ladder, not a frontier narrative
Parkinson's disease, multiple sclerosis, stroke and spinal cord injury have different mechanisms and established pathways. Laboratory promise or testimony is not clinical proof.
Define the disease, stage, current treatment and clinical goal before discussing cells. Symptom fluctuation, rehabilitation, medicine changes and natural recovery differ across neurological conditions. A result in one disease, cell product or route cannot be transferred to another.
Classify the evidence. Cell characterisation and laboratory mechanisms support a hypothesis; animal models test selected biological questions; early human studies may address feasibility and safety; controlled trials are needed to estimate benefit. Open-label change cannot separate an intervention effect from expectation, assessor bias, regression to the mean or concurrent care.
Specify the product and protocol: source, donor relationship, manipulation, differentiation state, dose, route, schedule, manufacturer, release tests and long-term monitoring. Neural progenitors, dopaminergic-cell products, haematopoietic transplantation, MSCs and exosomes are not interchangeable. Their risks and development stages differ.
Verify the authorised pathway and recruitment status directly. A registered study may be completed, withdrawn, not recruiting or located elsewhere; registration is not approval. Treatment outside an authorised trial requires a separate lawful basis, and payment does not turn an experimental product into routine care.
The FDA consumer page states that regenerative medicine therapies are not approved in the United States for neurological disorders such as multiple sclerosis, Alzheimer's disease, Parkinson's disease or stroke. Use the ISSCR clinical-translation guidance, the relevant regulator and an independent neurologist to assess an exact proposal.
Sources & further reading
- Stem-cell trials registry (ClinicalTrials.gov) ↗
- Peer-reviewed research (PubMed) ↗
- ISSCR — patient resources ↗
- FDA — consumer guidance ↗
- EMA — ATMP framework ↗
Commercial price observations are heterogeneous and most cell-therapy uses remain investigational. Verify source scope, regulatory status and the proposed care with an independent qualified physician.